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Abstract 
To date, the strongest predictor for dying with COVID-19 is suffering from several 
chronic disorders prior to the viral infection. Pre-existing multimorbidity is highly 
correlated with socioeconomic inequality. In turn, having several chronic conditions is 
closely linked to multiple medication intake, especially in richer countries with good 
access to biomedical care. Owing to its vertical structure, biomedicine often risks giving 
multiple treatments in an uncoordinated way. Such lack of integrated care can create 
complex forms of iatrogenic harm. Multimorbidity is often exacerbated by a 
pharmaceuticalization of social deprivation in place of integrated care. In this article, I 
explore the possibility that clusters of overmedication are a contributing factor to higher 
death rates from COVID-19, especially in poorer areas within richer countries. 
Anthropological perspectives on the social embeddedness of multimorbidity and 
multiple medication use can expand our understanding of who is most vulnerable to 
SARS-CoV-2. 
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"We really need to get data and we need to get data fast"
On March 18, 2020, Dr. Anthony Fauci and Dr. Howard Bauchner discussed a 
possible link between hypertension medications and a heightened risk of dying with a 
coronavirus infection. Bauchner is the Editor of JAMA, the Journal of the American 
Medical Association. Fauci directs the US National Institute of Allergy and Infectious 
Diseases. After joining the White House Coronavirus Task Force, Fauci became the 
world's most famous scientific advisor on COVID-19. In this conversation, Fauci 
highlighted possible links between ACE (angiotensin converting enzyme) inhibitors and 
COVID-19 fatalities. Fauci said that ACE inhibitors can increase "the expression of the 
receptors for the virus" (JN Learning 2020). Fauci was struck by reports from Italy that 
the vast majority of those who died with COVID-19 suffered from hypertension. Italy--
then the European epicenter of the pandemic--was a rich country with excellent access to 
medical care, and many COVID-19 victims had been taking ACE inhibitors to treat their 
hypertension. "Why should someone who has hypertension that's well controlled have a 
much greater chance of dying than somebody else with any other kind of underlying 
condition?," Fauci asked. "We really need to get data and we need to get data fast" (JN 
Learning 2020). Fauci’s concern is both about the clinic and the population. Significant 
patterns on a population level (here, Italian death rates) flag up patterns in clinical 
practice (widespread use of ACE inhibitors), which then lead to an exploration of 
pathogenesis (ACE inhibitors, cell receptors). I agree with Fauci that a careful 
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triangulation of pharmacological, clinical, epidemiological, and social science evidence is 
necessary to understand the action of the virus, how it spreads, and who is most 
vulnerable to it. 
In the months following Fauci’s call for data, a handful of medical articles appeared 
that examined the link between COVID-19 and antihypertensive drugs. The results were 
said to be inconclusive because none of the studies "adjusted for confounding variables" 
and so it remained unclear "if this association [between antihypertensives and high 
death rates] is related to the pathogenesis of hypertension or another associated 
comorbidity or treatment" (Patel & Verma 2020). The American Heart Association, a 
nonprofit organization that funds cardiological research and patient education, 
continued to recommend ACE inhibitors. In the absence of certainty about increased risk 
from ACE inhibitors, they told patients: "continue taking all your medications as 
prescribed, including ACE inhibitors … If you are diagnosed with COVID-19, you 
should be fully evaluated before adding or removing any treatments … your overall 
medical condition is much better if your blood pressure and diabetes are optimally 
controlled" (AHA 2020). 
Fauci's call that "we need to get data fast" was only heard for ACE inhibitors but not 
for other medications, and possible links between the pathogenesis of COVID-19 and 
complex medication patterns remain entirely unknown. I argue that Fauci's challenge 
remains as important now as it was at the beginning of the pandemic. There are at least 
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two ways that chronic pharmaceutical use might put people at a higher risk of dying 
with COVID-19. One is that medications could directly augment virulence and 
pathogenesis (as intimated by Fauci). Another is that overtreatment adds to the overall 
morbidity index, regardless of any specific drug mechanism, thus making an 
overmedicated patient less healthy and less able to resist succumbing to the disease. In 
what follows, I will explore the possibility that multiple medication intake may lead to 
poor outcomes for coronavirus by this pathway. My goal is to show how medical 
anthropology, especially an anthropology of pharmaceuticals, may add a less obvious 
path in explaining the global impact of COVID-19 than that taken by virologists or 
epidemiologists.
While the pandemic modelling first anticipated that the coronavirus would behave 
like influenza, researchers realized that COVID-19 is a "complex multi-system clinical 
syndrome" (Roberts et al. 2020) that has a completely different trajectory than influenza. 
According to clinical reports as of this writing, the virus starts to spread in the lungs but 
can go on to attack all other organs, including the brain. Even when a patient survives 
the virus infection, the long-term effects, such as cognitive impairment, psychological 
distress, or reduced lung capacity, can be severe and protracted. Some of the long-term 
harm may even be caused by "iatrogenic damage" (Roberts et al. 2020), which comes 
from clinical uncertainty over how to best treat those with severe COVID-19 symptoms. 
It is now better understood that treating COVID-19 as if it was a form of pneumonia, e.g. 
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by connecting all patients with low oxygen levels to ventilators, may do more harm than 
good (Marini and Gattinoni 2020). The pathogenesis I will explore here is the one that 
connects victims' multiple chronic health problems to the risks of dying with COVID-19 
specifically because of victims' multiple chronic medication histories. Could it be that 
socioeconomic deprivation coupled with chronic medication consumption is a predictor 
of dying with a SARS-CoV-2 infection? 
To date, one medical study has appeared that shows polypharmacy being strongly 
correlated with the risk of catching Sars-CoV-2. In an analysis of half a million UK 
biobank users, McQueenie and colleagues found “that there was a clear dose 
relationship whereby the risk of a COVID-19 positive test rose steadily with 
polypharmacy level” (2020: 15). This study did not identify which kinds of medications 
were used, and it only explored infection risks. 
My approach picks up on these threads from the medical literature to explore social 
factors linked to the spread and impact of the pandemic. First, I explore the social causes 
of multimorbidity and overmedication in relation to socioeconomic deprivation in one of 
the UK’s most deprived areas where I recently conducted fieldwork. I then offer case 
studies that demonstrate how multiple medication use exacerbates patients' health. In 
the final section I explore population-level links between chronic illness, chronic 
medication use, and dying from an acute coronavirus infection. My suggestion is that 
medication patterns should be considered in studies on pathogenesis and epidemiology. 
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COVID-19 death rates seem to be highest (1) where a country has high rates of 
multimorbidity; (2) where multimorbidity is deepened by high levels of social 
inequality; (3) where the health system enables easy access to multiple medications; and 
(4) where multiple chronic treatments are insufficiently integrated. In wealthy countries, 
COVID-19 appears to claim most victims in poorer pockets within richer regions, and 
complex medication regimes might be a missing piece in this puzzle. Anthropological 
perspectives might offer novel ways of conceptualizing not just the social but also the 
epidemiological contours of the pandemic as problems of “local biologies” (Lock and 
Nguyen 2018).
 
Uncovering multimorbidity
The clinical and epidemiological findings on COVID-19 and multimorbidity are, by 
now, fairly robust. From early on, medical reports fou d strong links between 
underlying health conditions and COVID-19. The majority of people infected with 
SARS-CoV-2, by some estimates 78%, remain asymptomatic (Day 2020). A minority of 
infected people experience mild to moderate flu symptoms. In perhaps 1% of people 
infected, COVID-19 turns fatal. Whether a SARS-CoV-2 infection kills seems highly 
correlated on the presence of pre-existing problems. The origins and forms of 
multimorbidity are thus extremely important for understanding global COVID-19 
mortality patterns. 
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Already the first studies of mortality in China's Wuhan city showed that almost all 
the people who died with the virus had pre-existing disorders (Novel Coronavirus 
Response Team 2020). The data from China highlighted heart disease, diabetes, chronic 
respiratory disease, high blood pressure, and cancer (Novel Coronavirus Response Team 
2020). Studies from around the world confirmed these findings. A study among patients 
admitted to New York City hospitals (Richardson, Hirsch & Narasimhan 2020) found 
similar conditions, especially hypertension (56.6% of COVID-19 patients), obesity 
(41.7%), and diabetes (33.8%). 21% of the COVID-19 patients admitted to NYC hospitals 
died. Using an assessment tool called the Charlson Comorbidity Index (CCI), which 
predicts 10-year survival rates in patients with multiple chronic problems, this study 
found that among all the patients admitted to New York City hospitals with a SARS-
CoV-2 infection, half were expected to die of existing morbidities within the next 10 
years. 
Forensic pathologists in the German city of Hamburg performed full autopsies on 
hundreds of COVID-19 victims. In every case they found one or more of these pre-
existing conditions: heart disease, asthma, chronic obstructive pulmonary disease, 
peripheral artery disease, diabetes, obesity, or a neurodegenerative disease (Wichmann, 
Sperhake, Lütgehetmann et al. 2020). The Hamburg study discovered at least one pre-
existing condition in every patient examined, and multimorbidity in the majority of 
cases. The findings from Hamburg were widely reported in German media. Dr. Klaus 
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Püschel, the Director of the Hamburg Institute for Forensic Medicine, argued that SARS-
CoV-2 is not nearly as serious a threat to the general population as it was believed to be. 
No one dies only of a SARS-CoV-2 infection, he said. At least one underlying health 
problem is always present (Wunder 2020). 
Multimorbidity occurs when the same person suffers from two or more chronic 
disorders, which can be noncommunicable, infectious, or mental (Academy of Medical 
Sciences 2018: 6). There is no agreed way of how to measure multimorbidity: some 
researchers classify multimorbidity by how many disorders occur together, while others 
look for systematic clusters among co-occuring problems. What problems are counted in 
one of these clusters also varies, some researchers consider only a handful of chronic 
disorders as constitutive of multimorbidity (Dugravot et al. 2020), while others capture 
dozens of conditions (Payne 2020). Multimorbidity overlaps with other constructs, such 
as "frailty" (Hanlon et al. 2018) and "disability" (Stineman 2012). 
The notion of "comorbidity," as the coexistence of an "index" disorder and a 
secondary disorder, emerged in the 1970s (Weaver, Barrett & Nichter 2016). Research 
into multimorbidity as a more complex category of diagnosis was almost inexistent a 
decade ago, but took off when the epidemic spread of co-occurring chronic disorders 
came into view (Busija et al. 2019: 1). Rising rates of multimorbidity have become a 
concern for both clinicians and epidemiologists. In rich countries, multimorbidity makes 
up 25-50% of the overall disease burden (Garin et al. 2016; van der Aa et al. 2017). In the 
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UK, for example, multimorbid conditions account for 50% of GP appointments, 64% of 
outpatient appointments, 70% of inpatient bed days, and 70% of total health 
expenditures (Aiden 2018: 4). Longer lifespans mean more multimorbidity: the older 
people are, the more chronic health problems they have. Up to two thirds of people over 
65 are multimorbid. Treating older patients accounts for the majority of all health 
expenditures (Kaufman 2015). 
Multimorbidity is strongly correlated with protracted medication uses. About half of 
older adults in richer countries are on five or more medications (Mangin & Garfinkel 
2019: 1). The pharmaceutical industry promotes the regular consumption of five or more 
medications as necessary for the maintenance of health. For the industry, chronic 
polypharmacy is recommended as the new normal because multimorbidity is now 
normal. Already a decade ago, people in richer countries were on nine to thirteen 
prescription drugs in any given year (Dumit 2012: 2). Regimes of chronic polypharmacy 
originated in the US in the 2000s but have become normalized across the world 
wherever drugs are affordable and accessible. 
Multimorbidity is not a new condition, as there have always been people with more 
than two health issues at the same time. But the growth of multimorbidity diagnoses and 
the biomedical focus on it are new. Dr. Chris Whitty, the UK government's chief advisor 
on COVID-19, argued in January 2020--just when the pandemic hit--that multimorbidity 
did not come into view for so long because biomedicine is organized "vertically" along 
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specific diseases, while a "horizontal" understanding of simultaneous disorders is 
lacking (Whitty et al. 2020: 1). Verticality increases the risk of iatrogenesis by way of 
multiple uncoordinated treatments. As others have shown, this verticality is itself an 
artefact of reliance on a biomedical model that tries to isolate causes of disorders and to 
develop therapies that are reductionistic (White 2006: 141-142). Although multimorbidity 
is a recognized and proliferating problem, research on the interactions between 
multimorbidity and protracted medication use is still largely absent.
Current biomedical research on multimorbidity could be of use in mapping possible 
research avenues in relation to Covid-19. Some of this explores nonrandom clusters of 
disorders (Academy of Medical Sciences 2018: 5; Busjia 2019). Other research explores 
how socioeconomic inequality congeals and expands chronic disease clusters. The most-
cited study on multimorbidity is by Barnett and colleagues (2012). In this study, Scottish 
patient health records were scrutinized, and showed a strong correlation between 
socioeconomic deprivation and multimorbid suffering. A decade ago, already 23.2% of 
all Scottish patients were multimorbid and a third of these multimorbid patients had 
both mental and physical problems. Socioeconomic deprivation shifted the onset of 
multimorbidity forward: “young and middle-aged adults living in the most deprived 
areas had rates of multimorbidity equivalent to those aged 10-15 older in the most 
affluent areas” (2012: 39). In deprived neighborhoods, people in their 40s and 50s are as 
likely to have multiple chronic problems as 60 or 70-year olds in the average population. 
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Barnett's (2012) quantitative results tally with qualitative studies on GPs' "endless 
struggle" with multimorbidity in deprived areas (O'Brien et al. 2011; Lawson et al. 2013). 
All available data suggest that multimorbidity keeps rising.
Even when multimorbidity is recognized by clinicians, there are few therapeutic 
protocols to deal with it (Guthrie et al. 2012). Given the logic of pharmaceutical 
industries, multimorbidity will continually escalate the number of pills required for 
treating the average patient. The more a health system is compartmentalized by 
specialization, the more likely it is that multimorbidity goes unrecognized as a problem 
of its own. Patients with multiple chronic problems experience biomedical care as 
lacking coherence (Schiøtz, Høst & Frølich 2016). 
Some of the most important work in anthropology on multimorbidity is on 
"syndemics," which are "aggregation[s] of two or more diseases or other health 
conditions in a population in which there is some level of deleterious biological or 
behaviour interface that exacerbates the negative health effects of any or all of the 
diseases involved" (Singer et al. 2017: 941). The syndemics approach "move[s] beyond 
common medical conceptualisations of comorbidity and multimorbidity" (ibid.) by 
emphasizing structural violence (Farmer 1996) and social suffering (Kleinman, Das & 
Lock 1997). Syndemics researchers identify a number of multimorbid cluster patterns. 
For example, Mendenhall (2012; 2016) describes a pattern of "violence, immigration, 
depression, type 2 diabetes, and abuse" (VIDDA) among Mexican immigrant women 
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living in the US. "Immigration" tears families apart and leads to social isolation. 
"Depression" is conditioned by traumatic childhood experiences and diminished self-
efficacy. "Diabetes" is co-constituted by gender roles and food preferences. "Structural 
violence" includes living in unsafe neighborhoods. Limited access to healthcare is 
regarded as another form of structural violence. 
A syndemics perspective helps to connect COVID-19 as "complex multi-system 
clinical syndrome" to multimorbidity, polyiatrogenesis, and social deprivation. In the 
next section, I will describe how people in a poor area of the UK experience 
multimorbidity and polyiatrogenesis, pointing to an as yet little explored syndemic 
pattern and also to possible ways we might rethink social vulnerability to SARS-CoV-2.
Overtreating the underprivileged
My research took place in one of the UK's most deprived areas, which I will call 
Greyfield. Similar to the pattern described by Mendenhall (2012; 2016), Greyfielders 
experience clusters of structural violence, depression, diabetes, and abuse. However, 
they were not immigrants and they had universal access to healthcare, provided free of 
charge by the National Health Service (NHS). Thus, even the poorest are frequently on 
multiple medications without any financial burdens on households. 
The population of Greyfield is largely white British. Most of the housing is made up 
of apartments in tower blocks and low-rises built in the 1960s and 1970s. The area saw 
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substantial redevelopments in the 1990s and 2000s. Despite some improvements, 
Greyfield still has some of the UK's worst scores for health, income, employment, 
education, and crime. Life expectancy of area residents is shockingly low at only 61 years 
on average, which is 20 years shorter than the average UK life expectancy. Greyfield's life 
expectancy is below that of Zimbabwe.
One of the infrastructural improvements to Greyfield since the 2000s was the 
construction of Greyfield Care Centre (GCC), a joint facility of the NHS and the local 
council. GCC tries to take a more integrated approach by combining different medical 
specializations (primary care, cancer support, dentistry, midwifery) with social services. 
GCC also houses a clinic for Lifestyle, Nutrition, and Complementary Therapy (LNC). 
My fieldwork was conducted in the LNC section of GCC. I analyzed 80 case files, 
discussed 30 selected cases with therapists, and shadowed 40 consultations. Most of the 
patients get referred to LNC by GPs in GCC. The patients that the LNC practitioners see 
are the same as those treated by the GPs, but LNC consultations allow far more time for 
patients to talk about their lives, their diets, and their medication regimes. LNC’s hour-
long, open-ended consultations allowed patients’ to explore complex problem in much 
greater depth than in the GP consultations, where patients were given no more than five 
or ten minutes. The average length of GP consultations in the NHS—nine minutes--is 
one of the lowest among OECD countries (Wardle 2019). In the NHS, patients’ time with 
GPs is extremely rationed, and longer consultations with a doctor are unavailable. 
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In LNC, Greyfield patients presented with a wide range of problems, but a few 
constellations came up repeatedly. Five or more co-occurring problems was the norm. 
The majority had mental problems along with physical problems. Traumatic life events 
were common. Chronically difficult social circumstances were nearly always present. 
Among various physical complaints, digestive diseases were virtually always present. 
Obesity was very common and was usually coupled with diabetes. Hypertension was 
pervasive. Physical problems appeared together with mental problems. Depression and 
anxiety were the most common mental illnesses.
Both mental and physical problems were often related to life trauma. Many traumatic 
events happened in relation to family members. Domestic violence and emotional abuse 
in intimate partnerships were common. Loss of family members, often at a young age, 
was another frequent source of trauma in this population. Miscarriages were also 
common. Haunting memories of losses suffered were a recurrent problem. Susan, a 
woman in her early 50s, for instance, first came to LNC because she wanted to lose 
weight and sleep better. In the first consultation, she broke down in tears. The sleep 
disturbance had started the previous year, when her brother died and one of her 
surgeries went wrong. She said her family was "broken": mother, father, cousins, uncles 
had all died, and her twin sister died when she was still a child. She said she often wakes 
up at night in a panic, as if a bright light was shining into her eyes. 
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Substance use was mentioned often by patients. Mostly, this referred to alcohol (for 
patients of all ages) and cannabis (among younger patients). Feeling "empty" or "bored" 
were patients’ explanations for why substances were used. Strong food aversions were 
also common. For example, Jack, a patient in his late 30s, complained about depression, 
panic attacks, acid reflux, sleep disturbance, and headaches. He also suffered from 
severe back pain, which two previous surgeries failed to make better. He traced his 
problems to his childhood: he was always disgusted by eating meat, but his parents 
forced it down his throat. In his experience, he said, the best remedy against the pain and 
the panic is smoking cannabis. Patients like Susan and Jack presented with complex 
multimorbidity in ways that are probably similar to many clinics in the world where a 
combination of poor diet, precarity, and multiple social traumas coalesce to cause or 
augment physical suffering. 
Despite the common presentation of patients at Greyfield, and despite the ample 
access to care they were provided, their overall state of health seemed often worsened by 
uncoordinated treatments. Molly’s experience exemplifies this vividly. Molly was a 37-
year-old woman born and raised in Greyfield. Molly came to LNC for a persistent pain 
in her foot. In the first consultation with Heather, the LNC practitioner, Molly added 
that she was also suffering from diabetes type II, that she wanted to lose weight, and that 
she could help with her irritable bowel syndrome (IBS). Molly was aware of the main 
food triggers for her IBS but she could not keep it in check. Molly said that her job as a 
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care worker was very stressful, especially when working late hours. She said her stress 
"gets to my stomach." Her bowel movements were very irregular. The first time she was 
diagnosed with IBS was when she was a child. She got some treatment and the problem 
was not too troubling until five years ago when she had a protracted and difficult 
breakup with her husband, during which she and her son suffered domestic abuse. That 
led, in turn, to lots of "behavioral problems" in her son that she was still struggling with. 
Asked by Heather if she had time left to look after herself, Molly said "my self-care is 
really bad, I know that it is really bad." 
Molly took a dose of Imodium every morning and had become completely 
dependent on it. Imodium (loperamide) is a common over-the-counter drug for acute 
diarrhea. The medication slows down the digestive process and should not be used for 
more than 48 hours. Molly complained about her daily eating habits, especially too 
many potato chips: ”Pringles are my downfall." Molly drank three to four litres of Coca-
Cola throughout the day: ”I am really bad with fizzy drinks." Asked if the GPs had 
explained the links between diabetes, blood sugar and high-sugar drinks, Molly said that 
the doctors did not yet have time to talk about food. Instead, they were “just firing 
tablets at me.” She had not been told by anyone face-to-face how to manage her diabetes. 
The LNC practitioner asked about Molly’s blood sugar readings, but Molly replied that 
she had no idea. Heather fetched a blood sugar kit and administered a test, by pricking 
one of Molly’s fingers and putting the blood in a glucose monitor. The reading showed 
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an extremely high glucose level of 17 mmol/L. Heather asked what medications Molly is 
on. Molly pulled a black rubbish bag out of her handbag and put it on the table: "my 
lucky bag of medicines,” she laughed. Molly said that she is taking two medformin (a 
standard tablet for diabetes) every morning, plus another diabetes medication. Heather 
said that Molly should find out how to monitor her blood sugar levels, not least because 
her levels are high despite already being on drugs. 
Molly unpacked seven other drugs from her “lucky” bag: an antidepressant 
(citalopram 20mg), propanonol (a beta-blocker, against the anxiety of having diarrhea 
while out of the house); Fianola, a contraceptive; an antihistamine for allergies; 
omeprazole against gastric reflux; gentamicin, an antibiotic drug; and a high-dose 
ibuprofen for the pain in the foot. Molly continued to unpack a number of alternative 
remedies, including sage pills and matcha green tea pills, which were meant to help her 
against “hot flashes.” She said that she is a “hot perso ,” “burning up very quickly,” and 
joked that she should “move to Iceland” to feel more comfortable. 
Heather asked about Molly’s body weight. She said she weighs about 20 stone. At her 
body height, her BMI was 45, putting her into the obese category. Molly said she has 
always been “big.” She then asked about a growth on her foot and showed it to Heather. 
A GP had told her it was a "ganglion." It caused her much pain and restricted her 
movement. By overcompensating with her other foot, she developed plantar fasciitis and 
dislocated a bone. She had phoned her GP about the ganglion but was told that there 
Page 17 of 38 Medical Anthropology Quarterly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
was nothing else they could do. Heather probes further about what kind of pain Molly 
has in her foot and is told it is like “pins and needles,” which Heather said might be 
related to the diabetes. Molly further said that she has not been told by any doctor what 
she could do about the plantar fasciitis. Drawing the consultation to a close, Heather said 
she does not want to prescribe any therapy yet. Instead, Molly should come back for a 
full assessment and then they would work out a care plan. Molly thanked Heather for 
taking so much time, saying that GPs only ever spoke to her briefly and only about a 
specific ailment. Heather went on to add that Molly should stop drinking fizzy drinks 
immediately. Molly asked if juices or fizzy water would be alright to have instead, but 
Heather told her that neither of them would be good for her, both for the sugar and for 
the fizz. 
 Molly’s case gives an insight into the “invisible epidemic” (Mangin and 
Garfinkel 2019) of patients with multiple health problems receiving multiple poorly 
integrated treatments that cause too often cause more harm than good. My point is not 
that Molly’s case is exceptional but rather that it is not exceptional at all. In fact, the 
cluster of multiple comorbidities experienced by Molly could be said to appear in 
syndemic form in many poor pockets of rich nations around the world. These pockets 
reveal high levels of multimorbidity and polyiatrogenesis. What I am suggesting is that 
such areas of social deprivation and overmedication might be at a substantially higher 
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risk from a virus that becomes particularly dangerous for people with multiple chronic 
conditions. 
Molly's overflowing bag of medicines is an example of how multimorbidity is 
deepened by the use of too many pharmaceuticals. I am not arguing that any single one 
of the GPs' treatments is irrational. What I am arguing is that a vertical system does not 
give physicians enough time to control for potentially iatrogenic effects, especially in 
chronic patients. When multiple single-target medications are coupled with a lack of 
explaining what is going on, the risks of overtreated ills become even greater. In an era 
of rising multimorbidity, biomedical specificity becomes part of a new kind of 
pathology. 
 What is so striking about multimorbid patients in the UK is that their poor health 
cannot be attributed to a biomedical treatment gap, in the way that this might be done in 
Mendenhall’s (2012) study on syndemics and structural violence in the US. The UK 
situation also differs from places like Brazil where poverty is heavily pharmaceuticalized 
(e.g., Scheper-Hughes 1992; Biehl 2005; Béhague 2015). In the UK, GPs are basically too 
short of time to treat complex patients in complex ways. They throw a pill at any ill in 
the belief that this constitutes good care while being unable to deal with the underlying 
problems and while losing sight of iatrogenesis. Greyfielders are deprived 
socioeconomically, but this deprivation does not translate into a lack of healthcare. The 
problem is a lack of integrated care. 
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Pharmaceuticalized pockets within richer regions
It is still early to know the links between multimorbidity, polyiatrogenesis, and 
COVID-19. As mentioned, there is not a single medical study yet on links between 
COVID-19 fatalities and multiple chronic medication uses. No one is tracking 
systematically what kind of medications COVID-19 victims are consuming when they 
get into hospitals with severe symptoms, let alone how chronic medication regimes 
interact with COVID-19 in the community setting. 
Even without this clinical evidence, it is possible to look for patterns on a population 
level. In the UK clinic I studied, high levels of multimorbidity and polyiatrogenesis were 
evident. If the hypothesis of chronic polypharmacy as a risk factor for COVID-19 holds, 
we would see higher rates of COVID-19 deaths in countries with high rates of 
multimorbidity, social inequality, ready access to biomedicine, and pronounced 
verticality in service delivery. What I found through ethnographic work in a UK clinic 
would lead to expect that death rates are indeed higher in the UK than in countries 
where this syndemic pattern is not as pronounced.
The global epidemiology of COVID-19 is still in flux, and many puzzles still have no 
convincing solution. Nevertheless, some epidemiological patterns have crystallized and 
remain fairly stable. First, we now know that the UK had become one of the world’s 
hardest-hit countries by May 2020. While it is still difficult to draw meaningful 
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comparisons between countries, there is solid evidence that the UK was exceptionally 
affected by the pandemic. By August 2020, the UK had one of the world's highest 
COVID-19 death rates, both by absolute numbers of victims (more than 50,000) and by 
fatalities per million population (685 compared to 94 in the world) (Our World in Data 
2020). The UK started to record "extremely high" excess death rates from week 13 
onward (EuroMOMO 2020). While most other European countries saw their excess 
death rates return to normal levels over the next three weeks, and while other nations 
saw their case fatality rate decline as more people tested positive without deadly 
outcomes, the UK continued to record "extremely high" excess rates for another eight 
weeks. Even the UK's nation-wide lockdown took two months to bring a significant 
reduction in death rates. In June, a full twelve weeks into lockdown, the UK recorded 
daily death rates higher than all other EU countries combined. The UK has done worse 
than most countries in the world, including the US. There were abject errors in the UK 
government's COVID-19 response (Horton 2020), but these policy failures cannot explain 
the UK’s exceptionally high death toll. 
Studies on European death rates consistently found correlations between social 
deprivation and dying with the virus: “COVID-19 is painfully exposing the existing and 
persisting health inequalities in our societies. This pandemic will have the heaviest 
impact on the lives of people living in deprivation or facing difficult socio-economic 
circumstances” (EuroHealthNet 2020). The UK showed the same pattern. Across 
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England, Wales, and Scotland, death rates were more than twice as high in 
socioeconomically deprived areas than in other areas. People in low-paid employment 
were dying at much higher rates than those in white-collar employment (New Statesman 
2020). Socioeconomic inequality is one of the strongest predictors for dying with COVID-
19 (Clark & Whiteley 2020). 
In the UK, as in practically all the European countries, social inequality does not 
translate into unequal access to biomedical care. In Greyfield and elsewhere in the UK, 
relative poverty does not mean less access. But no amount of clinical care can shield 
from dying with COVID-19. Docherty and colleagues' (2020) study on hospital outcomes 
in the UK found that the death rate of all patients admitted was 33%. In ICU units, 45% 
died. The UK is not an outlier in poor outcomes of hospital care. Reflecting on her 
gruelling experiences of giving intensive care to COVID-19 patients in New York City 
hospitals, Dr. Helen Ouyang (2020) realized that all the biomedical care in the world was 
unable to save people's lives: "What I think will actually cause moral injury is seeing 
people die after getting the most advanced care available. People who come in talking, 
with stories to share. They get care—the best that modern medicine has to offer—with 
life-prolonging machines and IV drips of all sorts of critical-care drugs. We put our full 
minds and whole hearts into trying to save them. Then I see their bodies shut down 
anyway." Even the best-equipped healthcare system offers no good defense against 
COVID-19. 
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Compared to other infectious diseases, COVID-19 behaves in an utterly surprising 
way. All other major infectious diseases—tuberculosis, HIV, or malaria—show a strong 
correlation between low GDP and high death rates. SARS-CoV-2 inverses this pattern 
on: so far, the impact of the virus was far more severe in rich countries than in low-
income countries. To be sure, the pandemic is still unfolding and what the situation 
might be in the long run is not known. And yet, to date high GDP and high COVID-19 
death rates are strongly correlated. By mid-August 2020, upper-middle and high-income 
countries suffered 90% of all COVID-19 deaths, despite having about half the world’s 
population. This pattern is so strange because infectious diseases usually strike much 
harder in poorer countries. 
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Until July 2020, all the world's countries with the highest per million population 
death rates lay in a corridor stretching from Northwest to Southwest Europe. Sweden, a 
country famous for not implementing a lockdown, only joined this group in the last days 
of May. Death rates per million population of 500 or more outside these European 
countries have so far only been reached in the US, Chile, and Peru, and that only since 
July. Viral infections usually take advantage of "multiple co-infections and biological and 
social vulnerabilities in a world where syndemics disproportionately affect marginalized 
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and less-resourced communities" (Manderson & Wahlberg 2020: 2). That means, 
practically without exception, that infectious diseases are far worse in poorer countries 
than in richer countries. COVID-19 turns this pattern on its head: all the hardest-hit 
countries are GDP-rich countries. COVID-19 does not seem to strike most where levels 
of absolute poverty are high, instead it hits the rich countries. There were some outliers, 
notably East Asian countries did far better than what their GDP per capita would lead to 
expect. The overall trend is clear, however. The world map of COVID-19 mortality does 
not show any Global North/South distributions along poor access to quality healthcare. 
Instead, the COVID-19 map looks like an atlas of rich industrialized countries with 
excellent clinical care. To be sure, GDP is a poor proxy for ease of access to biomedical 
treatments—US healthcare is a case in point. At the very least it safe to say that high 
income and excellent biomedical care do not protect against high COVID-19 death rates. 
The country-to-country comparison hides that relative deprivation within a wealthy 
context is a key risk factor for health (Ecks 2021). COVID-19 strikes poorer pockets within 
richer regions. Relatively deprived communities do not necessarily lack access to 
biomedical care. These communities may have high levels of multimorbidity within a 
context of relatively good healthcare access. Good access to healthcare clearly does not 
protect anyone from dying with COVID-19. In fact, easy access may translate into 
chronic overmedicalization, which in turn may make people more vulnerable to dying 
with the virus infection. The UK data on double mortality rates in poorer areas confirm 
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this pattern. Other countries with stark regional and local wealth disparities exhibit this 
pattern as well. Relative deprivation leads to higher rates of multimorbidity. 
Multimorbidity increases the risk of polyiatrogenesis, especially where treatments are 
accessible and affordable. It is possible that COVID-19 particularly affects multimorbid 
patients who are prematurely sick because of deep wealth inequalities and whose 
multimorbidity is exacerbated by polyiatrogenesis. 
It is possible that there are other factors at work that explain why GDP-rich countries 
have much higher death rates. Some of them are about GDP and global connectedness; 
others are about GDP and population age structure. SARS-CoV-2 probably first made 
impact along global air traffic routes, so that many poorer countries might have had a 
delayed exposure to the virus. But date of exposure seems unrelated to eventual death 
rates. Thailand, for example, was the first country outside China to record a SARS-CoV-2 
infection, on January 13, 2020. The country has a population of 69 million. By August, it 
had 58 deaths. The UK population is 66 million. The country recorded its first SARS-
CoV-2 case on 28 February 2020, seven weeks after Thailand. By August, the UK had 
more than 50,000 deaths. Per one fatality in Thailand there were 862 fatalities in the UK. 
Well into June 2020, the UK recorded five times more daily deaths than Thailand's entire 
death count in a population larger than the UK's. 
Many argue that richer countries, especially in North-Southwest Europe, became the 
global epicenter of the pandemic because people there have longer life expectancies and, 
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therefore, higher rates of multimorbidity. But longer life expectancies alone cannot 
explain any of these patterns. Among the Europeans, only Italians and Spaniards are in 
the top ten globally. The UK ranks only 29th in the world for life expectancy. Japan, Hong 
Kong and many other countries have much longer life expectancies than the UK, but are 
not nearly as much hit by the pandemic. The same point can be made about a 
population’s median age as a protective factor against high COVID-19 death rates. That 
low-income countries have younger populations and “therefore” have lower COVID-19 
death rates is taken as an obvious fact (e.g., Pulla 2020). But if median age were a vital 
factor, why would Peru have a COVID-19 death rate of 651 per million population at a 
median age of just 27.5 years? At 46.3 years, Japan has the world’s highest median age; at 
8 deaths per million population, Japan also has one of the world’s lowest COVID-19 
death rates. Neither a country’s life expectancy nor its median age seem to be decisive 
factors in COVID-19 death rates. 
To date, none of the available epidemiological and population data can confirm or 
disconfirm links between high rates of chronic medication uses and COVID-19 death 
rates. High GDP alone does not translate directly into high rates of pharmaceutical 
consumption, fragmented care, or deeper wealth disparities within countries. But the 
fact remains that the risk of dying with COVID-19 is not correlated with low income 
levels, as practically all other infectious diseases are. Nor is it related to poor healthcare 
access, as is the case with all other infectious diseases. Instead, epidemiology of COVID-
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19 seems to confirm that countries with high rates of multimorbidity, high levels of 
internal social inequality, and good health access are hardest hit. 
Checking COVID-19 victims not just for underlying health conditions but also for 
medication histories is the only way of knowing if there might be a link to chronic 
multiple medication use. Much more research is needed to figure out how susceptibility 
to dying with COVID-19 might be related to medication patterns. But to date, neither 
clinicians, epidemiologists, nor social scientists are studying this. We need to link 
COVID-19 deaths to clustered disorders and we need to link clustered disorders to 
clustered overmedication. The short ethnographic case study I presented here is only a 
tiny fragment in the work that needs to be done on experiences and causes of 
multimorbidity, chronic medication use, and polyiatrogenesis in a pandemic era. Both 
clinical and epidemiological findings are suggestive of links between relative 
socioeconomic deprivation, medication overuse, and susceptibility to the novel 
coronavirus. As long as there is no effective medication to treat COVID-19, clinicians 
should make sure that existing treatments for other medical conditions are used with 
greater care. 
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